Anika Therapeutics, Inc. ANIK
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 9.98% | 15.56% | 13.16% | 0.04% | -28.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.98% | 15.56% | 13.16% | 0.04% | -28.22% |
| Cost of Revenue | -3.89% | -17.97% | -7.59% | -11.14% | -67.22% |
| Gross Profit | 20.87% | 47.91% | 29.40% | 8.16% | 982.22% |
| SG&A Expenses | -2.90% | -16.79% | 25.41% | 6.68% | -37.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.42% | -10.85% | 10.05% | -2.38% | -51.23% |
| Operating Income | 81.91% | 189.14% | 8.94% | 752.53% | 87.02% |
| Income Before Tax | 85.60% | 185.22% | -24.61% | 1,858.97% | 91.90% |
| Income Tax Expenses | -101.17% | -89.57% | 164.04% | -141.07% | -59.30% |
| Earnings from Continuing Operations | 90.20% | 171.21% | -27.74% | 172.45% | 89.39% |
| Earnings from Discontinued Operations | -- | -- | -- | 92.21% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 86.65% | 183.35% | -3.76% | 101.34% | 92.22% |
| EBIT | 81.91% | 189.14% | 8.94% | 752.53% | 87.02% |
| EBITDA | 146.67% | 279.57% | 7.36% | 47.12% | 91.95% |
| EPS Basic | 85.63% | 189.80% | -9.65% | 101.37% | 92.03% |
| Normalized Basic EPS | 90.61% | 212.80% | 11.65% | 20.94% | 90.66% |
| EPS Diluted | 85.63% | 184.69% | -8.63% | 101.05% | 92.04% |
| Normalized Diluted EPS | 90.61% | 210.84% | 11.65% | 18.12% | 90.66% |
| Average Basic Shares Outstanding | -7.15% | -7.20% | -5.36% | -2.08% | -2.36% |
| Average Diluted Shares Outstanding | -7.15% | -5.51% | -5.36% | 0.31% | -2.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |